Machado-Joseph disease/spinocerebellar ataxia type 3.
Paulson H.
Handb Clin Neurol. 2012;103:437-49. doi: 10.1016/B978-0-444-51892-7.00027-9.
Reconstructing the History of Machado-Joseph Disease.
Meira AT, Pedroso JL, Boller F, Franklin GL, Barsottini OGP, Teive HAG.
Eur Neurol. 2020;83(1):99-104. doi: 10.1159/000507191. Epub 2020 Apr 28.
Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
Dantuma NP, Herzog LK.
Adv Exp Med Biol. 2020;1233:237-260. doi: 10.1007/978-3-030-38266-7_10.
Recent therapeutic prospects for Machado-Joseph disease.
Costa MDC.
Curr Opin Neurol. 2020 Aug;33(4):519-526. doi: 10.1097/WCO.0000000000000832.
Pharmacological Therapies for Machado-Joseph Disease.
Duarte-Silva S, Maciel P.
Adv Exp Med Biol. 2018;1049:369-394. doi: 10.1007/978-3-319-71779-1_19.
Animal Models of Machado-Joseph Disease.
Schmidt J, Schmidt T.
Adv Exp Med Biol. 2018;1049:289-308. doi: 10.1007/978-3-319-71779-1_15.
Clinical Features of Machado-Joseph Disease.
Mendonça N, França MC Jr, Gonçalves AF, Januário C.
Adv Exp Med Biol. 2018;1049:255-273. doi: 10.1007/978-3-319-71779-1_13.
Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy.
Matos CA, de Almeida LP, Nóbrega C.
J Neurochem. 2019 Jan;148(1):8-28. doi: 10.1111/jnc.14541. Epub 2018 Oct 5.
Origins and Spread of Machado-Joseph Disease Ancestral Mutations Events.
Martins S, Sequeiros J.
Adv Exp Med Biol. 2018;1049:243-254. doi: 10.1007/978-3-319-71779-1_12.
Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM, Jardim LB.
Adv Exp Med Biol. 2018;1049:321-348. doi: 10.1007/978-3-319-71779-1_17.
